Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 16/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.70 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.35 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1553268 | 0.91 | ADORA2A (0.67) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL1553964 | 0.90 | ADORA2A (0.71) | ADORA2AADORA1ADORA2BADORA3ACVRL1 | |
| SCHEMBL1553977 | 0.89 | ADORA2A (0.74) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL1553621 | 0.87 | ADORA2A (0.75) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL21176829 | 0.85 | ADORA2A (0.76) | ADORA2AADORA1ADORA2BADORA3BMPR1B | |
| SCHEMBL3455329 | 0.85 | ADORA2A (0.58) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL1554287 | 0.85 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL3456329 | 0.84 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL1553479 | 0.84 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL1553801 | 0.84 | ADORA2A (0.71) | ADORA2AADORA1ADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7396836-B2 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-07-08 | — | — | US | claimed |
| EP-1439175-B1 | PYRIMIDINE COMPOUND AND MEDICINAL COMPOSITION THEREOF | EISAI R&D MAN CO LTD (JP) | 2011-04-27 | — | — | EP | disclosed |
| EP-2246344-A1 | Pyrimidine compounds and medicinal composition thereof | Eisai R&D Management Co., Ltd. (JP) | 2010-11-03 | — | — | EP | disclosed |
| CN-100519549-C | Pyrimidine compounds and pharmaceutical compositions containing the same | EISAI R&D MAN CO LTD (JP) | 2009-07-29 | — | — | CN | disclosed |
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | HARADA HITOSHI | 2009-01-29 | — | — | US | disclosed |
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | HARADA HITOSHI | 2009-01-29 | — | — | US | disclosed |
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | HARADA HITOSHI | 2009-01-29 | — | — | US | disclosed |
| US-7396836-B2 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| US-7396836-B2 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| CN-1575290-A | Pyrimidine derivatives and pharmaceutical compositions containing that compounds | EISAI CO LTD (JP) | 2005-02-02 | — | — | CN | disclosed |
| US-20050004149-A1 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1439175-A1 | PYRIMIDINE COMPOUND AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | CBR3, AHR, HCCS | ADORA2A 539/4885ADORA1 328/4885ADORA2B 307/4885 |
| US-20050004149-A1 | Pyrimidine compound and medicinal composition thereof | ADORA2B, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA1 4/4885ADORA2B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.